Risk of breast cancer among users of aspirin and other antiinflammatory drugs.
British Journal of Cancer. 2004;91:525-529
ABSTRACT
We conducted a cohort study with a nested case-control analysis to
evaluate the effect of anti-inflammatory drugs in breast cancer
incidence using the General Practice Research Database. Women taking
aspirin and paracetamol for 1 year or longer had an odds ratio (OR) of
0.77 (95 percent confidence interval (95% CI): 0.62,0.95) and 0.76 (95%
CI: 0.65,0.88), respectively, compared to nonusers. Daily doses of
aspirin (75 mg) and paracetamol (up to 2000 mg) showed the greatest
reduced risk. Use of non-aspirin nonsteroidal anti-inflammatory drugs
for more than 1 year was not associated with a reduced risk of breast
cancer (OR=1.00 (95% CI: 0.84, 1.17)), and the corresponding estimate
among users with at least 2 years duration was similar. Our findings
suggest that aspirin at cardioprophylactic doses as well as paracetamol
at analgesic doses is associated with a reduced risk of breast cancer.